MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Issue 1 (April 2015)

• Record Type: Journal Article
• Authors: Wittig, Burghardt; Schmidt, Manuel; Scheithauer, Werner; Schmoll, Hans-Joachim
• Is Part Of: Critical reviews in oncology/hematology. Volume 94:Issue 1(2015)
• Page Start: 31
• Page End: 44
• Publication Date: 2015-04
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2014.12.002
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">TLR-9 agonists activate innate and adaptive immunity against cancer.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Chemically stabilized CpG-ODN type showed insufficient clinical efficacy.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Structure-stabilized MGN1703 is well tolerated at repeated applications of high doses.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Immune activation profile of MGN1703 holds therapeutic potential in variety of tumors.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">First-line switch maintenance trial in metastatic colorectal cancer is underway.</p> </list-item> </list> </p> </sec> </abstract>